It is known that SMARCB1 loss needs to happen during certain developmental stages for rhabdoid tumor development, whereas mainly lymphomas and benign tumors are formed at later phases (Han et al, 2016; Bracken et al, 2019; Parisian et al, 2020). Here, SMARCB1 is linked to benign neoplasm.